vimarsana.com

Latest Breaking News On - Diabetic macular edema - Page 2 : vimarsana.com

B C Retinal Treatment Program cuts dismay patients | Columbia Valley, East Kootenay, Kimberley, Ktunaxa Nation

4DMT Reports Full Year 2023 Financial Results and Operational Highlights

4DMT Reports Full Year 2023 Financial Results and Operational Highlights
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Oculis Provides Updates at R&D Day on Late-Stage Clinical Trials and Announces Key Leadership Appointments

EyePoint Pharmaceuticals: Innovating Eye Treatment, Yet A Hold At This Time (EYPT)

EyePoint Pharmaceuticals: Innovating Eye Treatment, Yet A Hold At This Time (EYPT)
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

Street likes Luna wet AMD phase II but Adverum wanes

With Adverum Biotechnologies Inc.’s preliminary safety and efficacy data made public from the ongoing Luna phase II trial testing gene therapy ixoberogene soroparvovec (ixo-vec) in wet age-related macular degeneration (AMD), Wall Street promptly began stacking the results against those of competitors. CEO Laurent Fischer pointed out that ixo-vec boasts the “highest rate of injection-free patients of any study of any program at any dose.”

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.